Thermo Fisher Scientific Inc. (NYSE:TMO) is Milestone Resources Group Ltd’s 9th Largest Position

Milestone Resources Group Ltd lowered its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 219,989 shares of the medical research company’s stock after selling 24 shares during the quarter. Thermo Fisher Scientific makes up 4.5% of Milestone Resources Group Ltd’s portfolio, making the stock its 9th biggest position. Milestone Resources Group Ltd owned 0.06% of Thermo Fisher Scientific worth $127,860,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. Avantax Advisory Services Inc. increased its holdings in shares of Thermo Fisher Scientific by 1.5% in the 1st quarter. Avantax Advisory Services Inc. now owns 22,739 shares of the medical research company’s stock valued at $13,216,000 after acquiring an additional 331 shares during the period. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund raised its holdings in Thermo Fisher Scientific by 20.6% in the first quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund now owns 90,845 shares of the medical research company’s stock worth $52,800,000 after purchasing an additional 15,495 shares in the last quarter. Hohimer Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 1.6% during the first quarter. Hohimer Wealth Management LLC now owns 1,676 shares of the medical research company’s stock valued at $974,000 after buying an additional 27 shares during the last quarter. Russell Investments Group Ltd. grew its position in shares of Thermo Fisher Scientific by 5.8% in the 1st quarter. Russell Investments Group Ltd. now owns 266,914 shares of the medical research company’s stock worth $155,094,000 after buying an additional 14,698 shares during the last quarter. Finally, Roffman Miller Associates Inc. PA raised its stake in shares of Thermo Fisher Scientific by 3.0% during the 1st quarter. Roffman Miller Associates Inc. PA now owns 34,501 shares of the medical research company’s stock worth $20,052,000 after acquiring an additional 1,008 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded up $10.77 on Tuesday, reaching $555.45. The company’s stock had a trading volume of 1,122,050 shares, compared to its average volume of 1,532,004. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The company has a market capitalization of $212.03 billion, a P/E ratio of 35.63, a PEG ratio of 2.56 and a beta of 0.77. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. The stock has a 50-day moving average price of $567.34 and a 200-day moving average price of $564.52.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.70 by $0.41. The business had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. Analysts expect that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, September 13th. This represents a $1.56 annualized dividend and a yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Analyst Ratings Changes

Several research firms have issued reports on TMO. Jefferies Financial Group reaffirmed a “buy” rating and issued a $650.00 price target (up from $600.00) on shares of Thermo Fisher Scientific in a report on Monday, June 3rd. Citigroup started coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target for the company. The Goldman Sachs Group increased their price objective on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Robert W. Baird decreased their price target on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a report on Thursday, April 25th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $605.63.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $70,873,516.56. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $70,873,516.56. The disclosure for this sale can be found here. Insiders have sold 22,000 shares of company stock valued at $12,532,780 in the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.